Analysis of two US administrative databases indicates that glucocorticoid use is associated with a dose-dependent increase in postoperative infection risk in patients with rheumatoid arthritis undergoing elective total knee or hip replacement.
In this podcast, we talk to Dana DiRenzo about the benefits of physical activity in patients with rheumatic diseases, as well as tools and strategies to enable patients to be more active.
Antonis Fanouriakis, lead author of the updated EULAR guidelines for the management of lupus, talks to medwireNews about what’s new in these guidelines and how they will influence clinical practice.
Psoriatic arthritis patients with multiple comorbidities have worse physical function than those with just one comorbidity, according to a cross-sectional analysis of the CARMA study of patients from daily clinical practice in Spain.
Rheumatoid arthritis patients receiving Janus kinase inhibitors may not be at increased risk for cardiovascular events in the short term, suggests a meta-analysis of randomized controlled trials comparing the active agents with placebo.
Analysis of two US administrative databases indicates that glucocorticoid use is associated with a dose-dependent increase in postoperative infection risk in patients with rheumatoid arthritis undergoing elective total knee or hip replacement.
Findings from the SENSCIS trial indicate that the tyrosine kinase inhibitor nintedanib reduces the annual rate of decline in forced vital capacity among patients with systemic sclerosis-associated interstitial lung disease.
The clinical benefit of infliximab dose escalation in people with rheumatoid arthritis may be limited to the initial two escalations, US study findings indicate.
Patients initiating their first tumor necrosis factor inhibitor for psoriatic arthritis have a longer time to discontinuation and are less likely to switch treatment than those previously treated with a drug from the same class, say researchers.
medwireNews takes a look at the efficacy and safety profiles of JAK inhibitors for the treatment of rheumatoid arthritis, and addresses some common questions about their use.
Analysis of data from the RA-BEAM and RA-BEYOND trials suggests that switching from adalimumab to baricitinib is associated with improvements in disease control and patient-reported outcomes in patients with rheumatoid arthritis, with an acceptable safety profile.
